Exact Sciences Corp
NASDAQ:EXAS
Exact Sciences Corp
Revenue
Exact Sciences Corp
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exact Sciences Corp
NASDAQ:EXAS
|
Revenue
$2.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
41%
|
CAGR 10-Years
90%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Exact Sciences Corp's Revenue?
Revenue
2.5B
USD
Based on the financial report for Dec 31, 2023, Exact Sciences Corp's Revenue amounts to 2.5B USD.
What is Exact Sciences Corp's Revenue growth rate?
Revenue CAGR 10Y
90%
Over the last year, the Revenue growth was 20%. The average annual Revenue growth rates for Exact Sciences Corp have been 19% over the past three years , 41% over the past five years , and 90% over the past ten years .